Study guide
9.2 HIV Pharmacotherapy, PrEP/PEP & Viral Hepatitis
Board Certified Ambulatory Care Pharmacist BCACP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Patient Care Process
1.1 BCACP Exam Logistics, Blueprint & Pass Standards 1.2 The Pharmacists' Patient Care Process (PPCP) in Ambulatory Care 1.3 Communication, Health Literacy & Cultural Competence
2 Chapter 2: Cardiovascular I: Hypertension & Dyslipidemia
2.1 Hypertension Guidelines, Staging & Primary Regimens 2.2 Resistant Hypertension, Secondary Causes & Special Populations 2.3 Dyslipidemia: Statin Benefit Groups & Non-Statin Add-ons
3 Chapter 3: Cardiovascular II: Heart Failure, CAD & Anticoagulation
3.1 Heart Failure GDMT: HFrEF Four Pillars & HFpEF Management 3.2 Chronic Coronary Disease & Antiplatelet Strategies 3.3 Anticoagulation: Atrial Fibrillation, VTE & Peri-Procedural Care
4 Chapter 4: Endocrine & Metabolic Disorders
4.1 Type 2 Diabetes: Incretins, SGLT2i & Comorbidity Alignment 4.2 Advanced Diabetes: Insulin Regimens, CGM & Hypoglycemia 4.3 Thyroid & Adrenal Disorders in Ambulatory Care 4.4 Osteoporosis Screening, Prevention & Therapeutic Sequencing
5 Chapter 5: Respiratory Care & Pulmonology
5.1 Asthma Management: GINA/NAEPP Stepwise & SMART Therapy 5.2 COPD Management: GOLD Guidelines & Exacerbation Prevention 5.3 Inhalation Devices, Delivery Techniques & Patient Counseling
6 Chapter 6: Renal, Urological & Reproductive Health
6.1 Chronic Kidney Disease: KDIGO Guidelines & SGLT2i/nsMRA Care 6.2 Benign Prostatic Hyperplasia & Erectile Dysfunction 6.3 Women's Health: Contraception, Menopause & Teratogenicity
7 Chapter 7: Neuropsychiatry & Behavioral Health
7.1 Major Depressive Disorder & Anxiety Disorders 7.2 Bipolar Disorder & Schizophrenia Spectrum 7.3 Epilepsy & Movement Disorders (Parkinson's Disease) 7.4 Migraine Prevention, Acute Treatment & Headache Disorders
8 Chapter 8: Pain Management & Rheumatology
8.1 Chronic Pain, Opioid Stewardship & SUD Management 8.2 Osteoarthritis, Gout & Hyperuricemia 8.3 Rheumatoid Arthritis & Autoimmune Pharmacotherapy
9 Chapter 9: Infectious Diseases & Immunizations
9.1 Ambulatory Infections & Outpatient Antimicrobial Stewardship 9.2 HIV Pharmacotherapy, PrEP/PEP & Viral Hepatitis 9.3 Adult Immunization Schedules & ACIP Recommendations 9.4 Immunizations in Special & High-Risk Populations
10 Chapter 10: Geriatrics, Drug Interactions & Medication Safety
10.1 Geriatric Pharmacotherapy, Beers Criteria & Deprescribing 10.2 Drug Interactions, CYP450, P-gp & Transporters 10.3 Adverse Drug Events, High-Alert Medications & ISMP Safety
11 Chapter 11: Biostatistics, Study Design & Literature Evaluation
11.1 Biostatistical Principles, Hypothesis Testing & Power 11.2 Clinical Study Designs, Bias & Evidence Appraisal 11.3 Pharmacoeconomics: ICER, QALY & Value Metrics
12 Chapter 12: Practice Advancement, Quality & Healthcare Delivery
12.1 Collaborative Practice Agreements & Telehealth Practice 12.2 Quality Improvement, HEDIS & CMS Star Ratings 12.3 Care Transitions, Medication Reconciliation & SDOH 12.4 CMM Services, CPT Coding (99605-99607) & Practice Management 12.5 Clinical Ethics, Patient Advocacy & Conflicts of Interest
9.2 HIV Pharmacotherapy, PrEP/PEP & Viral Hepatitis
Key Takeaways Explain This Topic AI
First-line initial antiretroviral therapy (ART) regimens are Integrase Strand Transfer Inhibitor (INSTI)-based: Biktarvy (bictegravir/FTC/TAF), dolutegravir + (FTC or 3TC) + (TAF or TDF), or Triumeq (dolutegravir/abacavir/lamivudine).
Mandatory HLA-B*5701 testing is required before initiating abacavir; if positive, abacavir is absolutely contraindicated due to fatal multisystem hypersensitivity reactions. Rechallenge is strictly prohibited.
Dovato (dolutegravir/lamivudine) is a 2-drug initial regimen contraindicated if viral load > 500,000 copies/mL, active Hepatitis B coinfection, or before resistance testing is available.
TAF yields 90% lower plasma tenofovir levels than TDF, significantly reducing renal tubular dysfunction and bone mineral density loss; TDF retains a favorable lipid-lowering profile.
DAAs achieve HCV cure (SVR12 > 95%) with 8 weeks of Mavyret or 12 weeks of Epclusa; screen for Hepatitis B reactivation prior to starting DAAs, and avoid co-administering sofosbuvir with amiodarone or velpatasvir with high-dose acid reducers.
Last updated: September 2026
HIV Pharmacotherapy, PrEP/PEP & Viral Hepatitis
Executive Summary: Antiretroviral therapy (ART) must be initiated in all individuals diagnosed with HIV immediately or as rapidly as possible , regardless of CD4 cell count, to reduce morbidity, mortality, and eliminate sexual transmission ( Undetectable = Untransmittable [U=U] ). Integrase Strand Transfer Inhibitor (INSTI)-based regimens form the cornerstone of modern initial therapy due to exceptional virologic potency, high genetic barriers to resistance, and minimal adverse effect profiles. In viral hepatitis, direct-acting antivirals (DAAs) achieve sustained virologic cure (>95%) in chronic Hepatitis C, while potent nucleos(t)ide analogues suppress Hepatitis B viral replication longitudinally.
1. Initial ART Regimens for Treatment-Naive Adults (DHHS Guidelines)
The Department of Health and Human Services (DHHS) Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents recommend that initial therapy for most people with HIV consist of an INSTI plus 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) (or 1 NRTI in a specific 2-drug regimen):
Preferred 3-Drug and 2-Drug Initial Regimens
Regimen (Brand Name) Components Formulation Key Clinical Considerations & Caveats
Biktarvy Bictegravir / Emtricitabine / Tenofovir Alafenamide (BIC / FTC / TAF 50/200/25 mg) Single Tablet Regimen (STR) 1 tab daily No HLA testing needed. High barrier to resistance. TAF minimizes bone and renal toxicity. Co-formulated, small tablet.
Dolutegravir + Descovy or Truvada Dolutegravir (DTG 50 mg) + (FTC / TAF 200/25 mg OR FTC / TDF 200/300 mg) 2 tablets once daily Highly potent, unboosted INSTI with excellent barrier to resistance. Flexible NRTI backbone selection based on renal and lipid status.
Triumeq Dolutegravir / Abacavir / Lamivudine (DTG / ABC / 3TC 50/600/300 mg) STR 1 tab daily MANDATORY HLA-B*5701 testing required prior to starting abacavir. Do NOT use if positive. Caution in high ASCVD risk patients.
Dovato (2-Drug Regimen) Dolutegravir / Lamivudine (DTG / 3TC 50/300 mg) STR 1 tab daily Indicated for initial therapy EXCEPT IF: viral load > 500,000 copies/mL, active Hepatitis B coinfection, or prior to resistance testing results.
Loading diagram... Initial Antiretroviral Therapy (ART) Selection & Safety Algorithm
- 2. Special ART Safety Principles, Toxicity Profiles & Drug Interactions
- Abacavir (ABC) Hypersensitivity & HLA-B*5701 Testing
Mechanism: Abacavir binds specifically within the antigen-binding groove of the HLA-B*5701 major histocompatibility complex (MHC) class I molecule, altering self-peptide presentation and triggering an uncontrolled, multi-organ cytotoxic T-cell hypersensitivity reaction (HSR).
Clinical Presentation: Multi-system syndrome characterized by fever, maculopapular rash, gastrointestinal distress (nausea, vomiting, diarrhea, abdominal pain), severe fatigue/malaise, and respiratory symptoms (cough, dyspnea, pharyngitis). Symptoms typically manifest within the first 6 weeks of therapy and worsen with each dose.
Absolute Rule: If a patient tests positive for HLA-B*5701 , abacavir is ABSOLUTELY CONTRAINDICATED and should be documented as a lifetime severe drug allergy. If abacavir is discontinued due to suspected HSR, NEVER RECHALLENGE THE PATIENT , as immediate, life-threatening anaphylactic collapse and death can occur within hours.
Tenofovir Comparison: TAF vs. TDF
Both agents are prodrugs of tenofovir, which is phosphorylated intracellularly to tenofovir diphosphate, a potent competitive inhibitor of HIV reverse transcriptase and HBV DNA polymerase.
Parameter Tenofovir Disoproxil Fumarate (TDF) Tenofovir Alafenamide (TAF)
Plasma Tenofovir Exposure High (rapidly cleaved in systemic circulation) ~90% lower (stable in plasma; cleaved intracellularly by cathepsin A in PBMCs)
Intracellular Tenofovir-DP Standard reference concentration 4-fold higher in target lymphoid cells
Renal Toxicity Higher risk of proximal renal tubular dysfunction (Fanconi syndrome) , proteinuria, decline in eGFR, and acute tubular necrosis. Significantly lower renal toxicity ; safe to initiate down to CrCl ≥ 30 mL/min (and on chronic hemodialysis for Biktarvy).
Bone Mineral Density (BMD) Greater decline in BMD, osteomalacia, and increased fracture risk. Significantly less BMD loss ; preferred in patients with osteopenia/osteoporosis or high FRAX fracture risk.
Lipid & Metabolic Profile Lipid-lowering effect (lowers total cholesterol, LDL-C, and triglycerides). Lipid-neutral (or slight increase in total/LDL cholesterol compared to TDF); associated with greater weight gain.
INSTI Polyvalent Cation Chelation Interactions
Mechanism: Integrase Strand Transfer Inhibitors (bictegravir, dolutegravir, raltegravir) utilize catalytic coordination with two divalent magnesium ions ( M g 2 + Mg^{2+} M g 2 + ) within the integrase active site. When co-administered orally with polyvalent metal cations ( A l 3 + , M g 2 + , C a 2 + , F e 2 + , F e 3 + , Z n 2 + Al^{3+}, Mg^{2+}, Ca^{2+}, Fe^{2+}, Fe^{3+}, Zn^{2+} A l 3 + , M g 2 + , C a 2 + , F e 2 + , F e 3 + , Z n 2 + ) present in antacids, multivitamins, and mineral supplements, chelation complexes form in the GI tract, reducing INSTI absorption by up to 70–90% and precipitating virologic failure.
Management Guidelines:
Antacids containing Aluminum / Magnesium: Administer INSTI at least 2 hours before or 6 hours after antacids.
Calcium or Iron Supplements: Dolutegravir and bictegravir can be taken simultaneously with calcium or iron supplements IF taken WITH FOOD . If taken on an empty stomach, separate by 2 hours before or 6 hours after.
- 3. Pre-Exposure Prophylaxis (PrEP) & Post-Exposure Prophylaxis (PEP)
- Pre-Exposure Prophylaxis (PrEP)
Indicated for HIV-negative individuals at ongoing substantial risk of HIV acquisition through sexual contact or injection drug use.
PrEP Modality Medication & Route Approved Populations & Indications Required Renal Cutoff & Clinical Notes
Daily Oral Truvada Emtricitabine / Tenofovir Disoproxil Fumarate (FTC / TDF 200/300 mg) PO daily All at-risk populations: Men who have sex with men (MSM), transgender men/women, heterosexually active men and women, and persons who inject drugs (PWID). CrCl ≥ 60 mL/min . Longest safety and efficacy track record. Check lipids and renal labs.
Daily Oral Descovy Emtricitabine / Tenofovir Alafenamide (FTC / TAF 200/25 mg) PO daily Cisgender men who have sex with men and transgender women at risk. NOT APPROVED for individuals at risk from receptive vaginal sex (due to lack of clinical trial efficacy data in cisgender females). CrCl ≥ 30 mL/min . Less renal and bone impact.
Long-Acting Injectable Apretude Cabotegravir (CAB 600 mg / 3 mL) IM gluteal Adults and adolescents weighing ≥ 35 kg at risk of sexual acquisition. Initiated with 1 injection at Month 0 and Month 1, then every 2 months thereafter. Optional 4-week oral lead-in with oral cabotegravir 30 mg daily. High barrier to resistance.
PrEP Monitoring Protocol
Baseline: Document negative HIV status within 7 days prior to initiation using a laboratory-based HIV-1/2 antigen/antibody immunoassay AND HIV-1 RNA qualitative/quantitative assay. Confirm HBV status (HBsAg); screen for STIs, renal function (eGFR, urine protein), and pregnancy.
Follow-up: Repeat HIV-1 RNA and Ag/Ab testing every 3 months for oral PrEP (or every 2 months before each cabotegravir injection); monitor eGFR semi-annually (or annually if <50 years with eGFR >90 mL/min).
Post-Exposure Prophylaxis (PEP / nPEP)
Timing Window: Must be initiated as urgently as possible within 72 hours of potential occupational (e.g., needlestick) or non-occupational (unprotected sexual encounter, shared needle, assault) exposure to HIV.
Duration: Exactly 28 continuous days of triple-drug ART.
Preferred Regimen: Dolutegravir (Tivicay 50 mg daily) OR Raltegravir (Isentress 400 mg BID) PLUS Truvada (FTC/TDF 200/300 mg daily) . (Biktarvy is also widely used off-label as an STR option in clinic protocols).
Follow-Up Testing: Baseline HIV test, repeat testing at 4–6 weeks and 3 months (12 weeks) post-exposure.
- 4. Viral Hepatitis: Chronic Hepatitis B (HBV) & Hepatitis C (HCV)
- Chronic Hepatitis B Virus (HBV)
Treatment Goals: Suppress HBV viral replication (HBV DNA), normalize ALT, prevent progression to cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC).
First-Line Oral Antivirals (High Genetic Barrier to Resistance):
Entecavir (ETV): 0.5 mg PO once daily on an empty stomach (at least 2 hours before or after meals). Dose is 1 mg daily in lamivudine-refractory patients or decompensated cirrhosis. Requires renal dose reduction.
Tenofovir Disoproxil Fumarate (TDF): 300 mg PO daily with or without food. Indicated in lamivudine resistance and pregnancy.
Tenofovir Alafenamide (Vemlidy - TAF): 25 mg PO daily with food. Preferred in patients with underlying renal dysfunction (CrCl ≥ 15 mL/min) or osteoporosis.
Black Box Warning: Severe acute exacerbations of hepatitis B have been reported in patients who discontinue anti-HBV therapy. Closely monitor hepatic function for several months following discontinuation.
Chronic Hepatitis C Virus (HCV) & Direct-Acting Antivirals (DAAs)
Direct-acting antivirals target specific non-structural viral proteins (NS3/4A protease, NS5A replication complex, and NS5B RNA polymerase) to achieve a Sustained Virologic Response at 12 weeks post-treatment (SVR12) , which equates to virologic cure in >95% of patients. ┌────────────────────────────────────────────────────────────────────────┐
- │ PANGENOTYPIC DAA REGIMENS (HCV) │
- ├──────────────────────────────────┬─────────────────────────────────────┤
- │ MAVYRET (Glecaprevir/Pibrentasvir│ EPCLUSA (Sofosbuvir/Velpatasvir) │
- │ • 3 tablets PO ONCE DAILY w/ food│ • 1 tablet PO ONCE DAILY w/ or w/o │
- │ • DURATION: 8 WEEKS (Naive, +/- │ • DURATION: 12 WEEKS (Naive, +/- │
- │ compensated Child-Pugh A) │ compensated Child-Pugh A) │
- │ • Safe in ANY renal function │ • Avoid PPIs or take Epclusa w/ food│
- │ (including Stage 5 CKD/HD) │ 4h before omeprazole ≤20 mg │
- │ • Check statin interactions! │ • AMIODARONE STRICTLY CONTRAINDICATED│
- └──────────────────────────────────┴─────────────────────────────────────┘
- DAA Drug Interactions & Clinical Pearls
Black Box Warning (HBV Reactivation): All patients initiating DAA therapy must be screened for evidence of current or prior HBV infection ( HBsAg and anti-HBc ). DAA clearance of HCV allows latent HBV replication to surge, potentially precipitating fulminant hepatic failure. If HBsAg is positive, initiate concurrent anti-HBV therapy.
Amiodarone + Sofosbuvir Contraindication: Co-administration of sofosbuvir-containing regimens (Epclusa, Harvoni, Vosevi) with amiodarone causes severe, symptomatic bradycardia and fatal cardiac arrest. Amiodarone is strictly contraindicated.
Acid-Reducing Agents with Velpatasvir (Epclusa): Velpatasvir requires an acidic gastric environment for oral dissolution and absorption:
Antacids: Separate by at least 4 hours.
H 2 H_2 H 2 -Receptor Antagonists (Famotidine): Administer simultaneously with Epclusa or 12 hours apart (dose ≤ \le ≤ 40 mg BID equivalent).
Proton Pump Inhibitors (Omeprazole): Avoid if possible. If medically necessary, administer Epclusa with food 4 hours before omeprazole ≤ \le ≤ 20 mg daily .
Statin Interactions with Protease Inhibitors (Glecaprevir / Mavyret): NS3/4A protease inhibitors inhibit OATP1B1/1B3 hepatic transporters and BCRP, dramatically increasing statin plasma concentrations. Simvastatin and high-dose atorvastatin are contraindicated; rosuvastatin must not exceed 10 mg daily.